20 July 2023 - Trodelvy has now improved survival in both pre-treated HR+/HER2- metastatic breast cancer and in second-line metastatic triple negative breast cancer.

Gilead Sciences today announced that Health Canada has issued a Notice of Compliance for Trodelvy (sacituzumab govitecan) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Read Gilead press release